A citation-based method for searching scientific literature

Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni, Hiroshi Hiai, Wataru Mizunoya, Tohru Fushiki, Jens Juul Holst, Mitsuhiro Makino, Akira Tashita, Yukari Kobara, Yoshiharu Tsubamoto, Takayoshi Jinnouchi, Takahito Jomori, Yutaka Seino. Nat Med 2002
Times Cited: 604







List of co-cited articles
1373 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
227
56

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
279
46

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
55
67

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
109
35

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
59
57


GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis.
Su-Jin Kim, Cuilan Nian, Subashini Karunakaran, Susanne M Clee, Carlos M Isales, Christopher H S McIntosh. PLoS One 2012
82
39

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
123
30

Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions.
Daniela Nasteska, Norio Harada, Kazuyo Suzuki, Shunsuke Yamane, Akihiro Hamasaki, Erina Joo, Kanako Iwasaki, Kimitaka Shibue, Takanari Harada, Nobuya Inagaki. Diabetes 2014
106
29

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
Paula L McClean, Nigel Irwin, Roslyn S Cassidy, Jens J Holst, Victor A Gault, Peter R Flatt. Am J Physiol Endocrinol Metab 2007
176
27

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
738
27

Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice.
Erina Joo, Norio Harada, Shunsuke Yamane, Toru Fukushima, Daisuke Taura, Kanako Iwasaki, Akiko Sankoda, Kimitaka Shibue, Takanari Harada, Kazuyo Suzuki,[...]. Diabetes 2017
40
65

Reappraisal of GIP Pharmacology for Metabolic Diseases.
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
78
32



A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
301
23

A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Pia K Nørregaard, Maria A Deryabina, Pernille Tofteng Shelton, Jacob U Fog, Jens R Daugaard, Per-Olof Eriksson, Lone F Larsen, Lene Jessen. Diabetes Obes Metab 2018
40
55


Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan,[...]. Cell Metab 2019
45
46

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor.
Meena Asmar, Ali Asmar, Lene Simonsen, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Bolette Hartmann, Flemming Dela, Jens Juul Holst, Jens Bülow. Diabetes 2017
51
39

Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.
A H Sparre-Ulrich, L S Hansen, B Svendsen, M Christensen, F K Knop, B Hartmann, J J Holst, M M Rosenkilde. Br J Pharmacol 2016
50
38

Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice.
Michael O Boylan, Patricia A Glazebrook, Milos Tatalovic, M Michael Wolfe. Am J Physiol Endocrinol Metab 2015
29
65


Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
706
19

Functional GIP receptors are present on adipocytes.
R G Yip, M O Boylan, T J Kieffer, M M Wolfe. Endocrinology 1998
165
18

Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.
Tanya Hansotia, Adriano Maida, Grace Flock, Yuichiro Yamada, Katsushi Tsukiyama, Yutaka Seino, Daniel J Drucker. J Clin Invest 2007
199
18

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Lærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, Mette H Jensen, Maria B N Gabe, Alexander H Sparre-Ulrich, Simon Veedfald, Signe Stensen, Amalie R Lanng, Natasha C Bergmann,[...]. Diabetes 2019
51
35

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
Natasha C Bergmann, Asger Lund, Lærke S Gasbjerg, Emma C E Meessen, Maria M Andersen, Sigrid Bergmann, Bolette Hartmann, Jens J Holst, Lene Jessen, Mikkel B Christensen,[...]. Diabetologia 2019
37
48

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition.
Kentaro Kaneko, Yukiko Fu, Hsiao-Yun Lin, Elizabeth L Cordonier, Qianxing Mo, Yong Gao, Ting Yao, Jacqueline Naylor, Victor Howard, Kenji Saito,[...]. J Clin Invest 2019
28
64

TCF1 links GIPR signaling to the control of beta cell function and survival.
Jonathan E Campbell, John R Ussher, Erin E Mulvihill, Jelena Kolic, Laurie L Baggio, Xiemen Cao, Yu Liu, Benjamin J Lamont, Tsukasa Morii, Catherine J Streutker,[...]. Nat Med 2016
66
25

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
17

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.
K Miyawaki, Y Yamada, H Yano, H Niwa, N Ban, Y Ihara, A Kubota, S Fujimoto, M Kajikawa, A Kuroe,[...]. Proc Natl Acad Sci U S A 1999
348
16



GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.
Lærke S Gasbjerg, Mikkel B Christensen, Bolette Hartmann, Amalie R Lanng, Alexander H Sparre-Ulrich, Maria B N Gabe, Flemming Dela, Tina Vilsbøll, Jens J Holst, Mette M Rosenkilde,[...]. Diabetologia 2018
47
31

Vaccination against GIP for the treatment of obesity.
Alma Fulurija, Thomas A Lutz, Katja Sladko, Melania Osto, Peter Y Wielinga, Martin F Bachmann, Philippe Saudan. PLoS One 2008
70
21

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
173
15

A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity.
Sameer Mohammad, Rajesh T Patel, Joanne Bruno, Muhammad Siyab Panhwar, Jennifer Wen, Timothy E McGraw. Mol Cell Biol 2014
45
33

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A Killion, Shu-Chen Lu, Madeline Fort, Yuichiro Yamada, Murielle M Véniant, David J Lloyd. Endocr Rev 2020
18
83

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
920
14

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
351
14

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index.
Elizabeth K Speliotes, Cristen J Willer, Sonja I Berndt, Keri L Monda, Gudmar Thorleifsson, Anne U Jackson, Hana Lango Allen, Cecilia M Lindgren, Jian'an Luan, Reedik Mägi,[...]. Nat Genet 2010
14

On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans.
Meena Asmar, Winnie Tangaa, Sten Madsbad, Kristine Hare, Arne Astrup, Anne Flint, Jens Bülow, Jens Juul Holst. Am J Physiol Endocrinol Metab 2010
52
26


A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
13

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
S J Henderson, A Konkar, D C Hornigold, J L Trevaskis, R Jackson, M Fritsch Fredin, R Jansson-Löfmark, J Naylor, A Rossi, M A Bednarek,[...]. Diabetes Obes Metab 2016
109
13


N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.
L S Hansen, A H Sparre-Ulrich, M Christensen, F K Knop, B Hartmann, J J Holst, M M Rosenkilde. Br J Pharmacol 2016
47
27

Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification.
Lisa Getty-Kaushik, Diane H Song, Michael O Boylan, Barbara E Corkey, M Michael Wolfe. Obesity (Silver Spring) 2006
78
16

Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
Peter Ravn, Chaithanya Madhurantakam, Susan Kunze, Evelyn Matthews, Claire Priest, Siobhan O'Brien, Andie Collinson, Monika Papworth, Maria Fritsch-Fredin, Lutz Jermutus,[...]. J Biol Chem 2013
56
23


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.